avapro has been researched along with Diabetes Mellitus, Type 1 in 11 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AT-II)-receptor-antagonists have been demonstrated to cause fetotoxicity when administered to women during the second and third trimester of pregnancy." | 7.73 | Teratogenicity with angiotensin II receptor antagonists in pregnancy. ( Boix, E; Moreno, O; Picó, A; Zapater, P, 2005) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AT-II)-receptor-antagonists have been demonstrated to cause fetotoxicity when administered to women during the second and third trimester of pregnancy." | 3.73 | Teratogenicity with angiotensin II receptor antagonists in pregnancy. ( Boix, E; Moreno, O; Picó, A; Zapater, P, 2005) |
| "Previously, we have demonstrated that patients with normoalbuminuric Type 1 diabetes are characterized by impaired nitric oxide bioavailability compensated for by increased vasodilatory prostanoid-mediated vasodilation." | 2.72 | Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial. ( Allard, SE; Browne, DL; Cummings, MH; Meeking, DR; Munday, JL; Shaw, KM, 2006) |
| "Irbesartan and creatinine clearance in NIDDM patients." | 2.40 | Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system. ( Hollenberg, NK, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Jacobsen, P | 2 |
| Andersen, S | 2 |
| Rossing, K | 2 |
| Jensen, BR | 1 |
| Parving, HH | 2 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| Chiarelli, F | 1 |
| Di Marzio, D | 1 |
| Santilli, F | 1 |
| Mohn, A | 1 |
| Blasetti, A | 1 |
| Cipollone, F | 1 |
| Mezzetti, A | 1 |
| Verrotti, A | 1 |
| Salcedo-Alejos, M | 1 |
| Banda-Espinoza, F | 1 |
| Rodríguez-Morán, M | 1 |
| Guerrero-Romero, F | 1 |
| Browne, DL | 1 |
| Meeking, DR | 1 |
| Allard, SE | 1 |
| Munday, JL | 1 |
| Shaw, KM | 1 |
| Cummings, MH | 1 |
| Boix, E | 1 |
| Zapater, P | 1 |
| Picó, A | 1 |
| Moreno, O | 1 |
| Wong, DW | 1 |
| Oudit, GY | 1 |
| Reich, H | 1 |
| Kassiri, Z | 1 |
| Zhou, J | 1 |
| Liu, QC | 1 |
| Backx, PH | 1 |
| Penninger, JM | 1 |
| Herzenberg, AM | 1 |
| Scholey, JW | 1 |
| Hollenberg, NK | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Hansen, BV | 1 |
4 reviews available for avapro and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 1997 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
5 trials available for avapro and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Comp | 2003 |
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.
Topics: Adolescent; Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Case-Co | 2005 |
Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Child; Creatinine; Diabetes | 2005 |
Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial.
Topics: Acetylcholine; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; C | 2006 |
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2002 |
2 other studies available for avapro and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Teratogenicity with angiotensin II receptor antagonists in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Bipheny | 2005 |
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.
Topics: Actins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Anima | 2007 |